home / stock / crdl / crdl articles
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...
On Tuesday, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administer...
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence ...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
(NewsDirect) In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study topline results. The Canadian biotechnology compan...
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRx™ also shown to reduce inflammation in patients with elevated CRP 89% of patients have continued into the extension phase of the study Toronto, Ontario--(Newsfile...
(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...